A Phase 1 clinical trial involving UB-313, a calcitonin-related investigational compound, has been updated to completed status as of November 4, 2026. The study, registered as NCT05477095, is titled "A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants." According to the trial record, the study enrolled healthy participants and assessed safety, tolerability, and immunogenicity in a Phase 1 setting. The listing confirms the trial has reached completed status but does not include results data in this update. No outcome measures, efficacy findings, or adverse event summaries are provided as part of this status change. The trial registry entry can be reviewed directly for further procedural details. Calcitonin remains an approved compound, and this Phase 1 study represents a related investigational formulation identified as UB-313. Readers interested in the background of calcitonin as an approved therapeutic agent can consult the compound overview for additional context.
Calcitonin-Related UB-313 Phase 1 Trial Marked Completed
See the full calcitonin overview
Source: https://clinicaltrials.gov/study/NCT05477095